Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay
G. Palmieri et al., Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay, J CL ONCOL, 19(5), 2001, pp. 1437-1443
Purpose: Detection of occult metastasis before the development of clinical
disease could allow more accurate staging, appropriate follow-up procedures
, and adjuvant therapies in patients with malignant melanoma (MM). The sent
inel lymph node (SLN) has been proposed as a reliable predictor of metastat
ic disease in the lymphatic basin draining the primary melanoma. In this st
udy, we screened both paraffin-embedded SLNs and peripheral-blood (PB) samp
les from MM patients at various stage of disease using a multimarker revers
e transcriptase polymerase chain reaction (RT-PCR) assay. The prognostic si
gnificance of the presence of PCR-positive markers was also evaluated.
Patients and Methods: Total RNA was obtained from paraffin-embedded SLN sec
tions and PB samples of 75 MM patients. RT-PCR was performed using tyrosina
se and MelanA/MART1 as melanoma-associated markers. Radiolabeled PCR produc
ts were analyzed on denaturing polyacrylamide gels.
Results: Good sensitivity of the RT-PCR assay on archival tissues was demon
strated after comparison of RT-PCR results on frozen and paraffin-embedded
SLNs from 16 MM patients. Significant correlation between the disease stage
and marker expression in both PB and SLN samples was observed; the highest
value was for patients who were positive for both markers in SLN (P =.006)
. Progression of disease was significantly associated with the total number
of PCR-positive markers in both PB (P =.034) and SLN (P =.001) samples.
Conclusion: Although sensitivity is lowered by the use of paraffin-embedded
specimens, our data indicate that RT-PCR analysis of serial sections from
archival SLNs may be helpful in improving detection of occult micrometastas
es, thus improving staging of patients with melanoma. J Clin Oncol 19:1437-
1443. (C) 2001 by American Society of Clinical Oncology.